Celltrion steps up global expansion with biosimilar drug
Aug 12, 2015
Celltrion, a South Korean biopharmaceutical company, is making headway in a newly emerging category of medicine known as biosimilars -- lower-cost copies of brand-name biologic drugs that have lost patent protection, around the world. The Korean drugmaker on Monday said it has gained approval from Australia to begin selling Remsima -- its biosimilar replication of the world’s third best-selling rheumatoid arthritis treatment drug Remicade. U.S.-based global pharmaceutical firm Hospira, Celltrio